




VISION IDE TRIAL


SAFETY & EFFICACY ENDPOINTS FROM PRIMARY COHORT

130 PATIENTS | 20 SITES | 164 LESIONS | 7.3 ± 4.1cm MEAN LESION LENGTH | SFA-POPLITEAL LESION LOCATION

LUMINAL GAIN | 72%




ADVENTITIA | 1.1%



SAFETY | 0 EVENTS



OUTCOMES | 92% FTLR






FOLLOW-UP COMPARATIVE DATA

OUTCOMES FROM VISION 24-MONTH FULL COHORT DATA AND EUROPEAN CASE SERIES


FREEDOM FROM TLR

SOURCE: VISION



FREEDOM FROM TLR & PRIMARY PATENCY*

SOURCE: EUROPEAN CASE SERIES (GRAZ, AUSTRIA) BY LESION



*Patency is defined by PSVR <2.4